Myeloperoxidase (MPO) is a member of the heme peroxidase superfamily and is stored within the azurophilic granules of leukocytes.¹ MPO is found within circulating neutrophils, monocytes, and some tissue macrophages.² A unique activity of MPO is its ability to use chloride as a cosubstrate with hydrogen peroxide to generate chlorinating oxidants such as hypochlorous acid, a potent antimicrobial agent.³ Recently, evidence has emerged that MPO-derived oxidants contribute to tissue damage and the initiation and propagation of acute and chronic vascular inflammatory diseases.^4,5 The fact that circulating levels of MPO have been shown to predict risks for major adverse cardiac events and that levels of MPO-derived chlorinated compounds are specific biomarkers for disease progression, has attracted considerable interest in the development of therapeutically useful MPO inhibitors.⁶ MPO also oxidizes a variety of substrates, including phenols and anilines, via the classic peroxidation cycle. The relative concentrations of chloride and the reducing substrate determine whether MPO uses hydrogen peroxide for chlorination or peroxidation. Assays based on measurement of chlorination activity are more specific for MPO than those based on peroxidase substrates because peroxidases generally do not produce hypochlorous acid. However, it is important that when screening for MPO inhibition that both the chlorination and peroxidation activities be tested. This determines whether the inhibitor specifically interferes with the chlorination and/or peroxidation cycle or whether the inhibitor simply acts as a scavenger for hypochlorous acid. Also, many reversible inhibitors act by diverting MPO from the chlorinating cycle to the peroxidase cycle. Cayman’s MPO Inhibitor Screening Assay provides convenient fluorescence-based methods for screening inhibitors to both the chlorination and peroxidation activities of MPO. The chlorination assay utilizes the non-fluorescent 2-[6-(4-aminophenoxy)-3-oxo-3H-xanthen-9-yl]-benzoic acid (APF), which is selectively cleaved by hypochlorite (-OCl) to yield the highly fluorescent compound fluorescein.⁷ Fluorescein fluorescence is analyzed with an excitation wavelength of 480-490 nm and an emission wavelength of 515-520 nm. The peroxidation assay utilizes the peroxidase component of MPO. The reaction between hydrogen peroxide and ADHP (10-acetyl-3,7-dihydroxyphenoxazine) produces the highly fluorescent compound resorufin. Resorufin fluorescence is analyzed with an excitation wavelength of 530-540 nm and an emission wavelength of 585-595 nm.

1 Yamada, M., and Kurahashi, K. Regulation of myeloperoxidase gene expression during differentiation of human myeloid leukemia HL-60 cells. J Biol Chem 259(5) 3021-3025 (1984).

2 Schultz, J., and Kaminker, K. Myeloperoxidase of the leucocyte of normal human blood.1 I. Content and localization. Arch Biochem Biophys 96 465-467 (1962).

3 Harrison, J.E., and Schultz, J. Studies on the chlorinating activity of myeloperoxidase. J Biol Chem 251(5) 1371-1374 (1976).

4 Podrez, E.A., Abu-Soud, H.M., and Hazen, S.L. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med 28(12) 1717-1725 (2000).

5 Zhang, R., Brennan, M., Fu, X., et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286(17) 2136-2142 (2001).

6 Malle, E., Furtmüller, P.G., Sattler, W., et al. Myeloperoxidase: A target for new drug development? Br J Pharmacol 152 838-854 (2007).

7 Setsukinai, K., Urano, Y., Kakinuma, K., et al. Development of novel fluorescence probes that can reliably detect reactive oxygen species and distinguish specific species. J Biol Chem 278(5) 3170-3175 (2003).

Setsukinai, K., Urano, Y., Kakinuma, K., et al. Development of novel fluorescence probes that can reliably detect reactive oxygen species and distinguish specific species. J Biol Chem 278(5) 3170-3175 (2003).

Kettle, A.J., Gedye, C.A., and Winterbourn, C.C. Mechanism of inactivation of myeloperoxidase by 4-aminobenzoic acid hydrazide. Biochem J 321 503-508 (1997).

Yamada, M., and Kurahashi, K. Regulation of myeloperoxidase gene expression during differentiation of human myeloid leukemia HL-60 cells. J Biol Chem 259(5) 3021-3025 (1984).

Schultz, J., and Kaminker, K. Myeloperoxidase of the leucocyte of normal human blood.1 I. Content and localization. Arch Biochem Biophys 96 465-467 (1962).

Harrison, J.E., and Schultz, J. Studies on the chlorinating activity of myeloperoxidase. J Biol Chem 251(5) 1371-1374 (1976).

Podrez, E.A., Abu-Soud, H.M., and Hazen, S.L. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med 28(12) 1717-1725 (2000).

Zhang, R., Brennan, M., Fu, X., et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286(17) 2136-2142 (2001).

Malle, E., Furtmüller, P.G., Sattler, W., et al. Myeloperoxidase: A target for new drug development? Br J Pharmacol 152 838-854 (2007).

Kettle, A.J., Gedye, C.A., Hampton, M.B., et al. Inhibition of myeloperoxidase by benzoic acid hydrazides. Biochem J 308 559-563 (1995).

Show all 9 Hide all but first 3